Significant prognostic factors on multivariate analysis for survivals in patients with newly diagnosed APL
| Prognostic indicators . | P value . | HR for inferior survival . | 95% CI . |
|---|---|---|---|
| 60-d survival | |||
| CNS involvement at diagnosis | |||
| Absent | <.001 | 0.06 | 0.03-0.13 |
| Present | 15.95 | 7.56-33.63 | |
| Induction regimens | |||
| Non-ATO containing | <.001 | 5.33 | 2.30-12.35 |
| ATO containing | 0.19 | 0.08-0.44 | |
| Treatment groups | |||
| ATRA/chemotherapy | <.001 | 5.53 | 2.24-13.68 |
| IV-ATO/ATRA | 0.22 | 0.03-1.68 | |
| Oral-AAA | 0.18 | 0.07-0.45 | |
| Post–60-d OS | |||
| Sex | |||
| Male | .02 | 1.87 | 1.12-3.11 |
| Female | 0.54 | 0.32-0.90 | |
| Age | |||
| ≤50 y | .04 | 0.60 | 0.36-0.97 |
| >50 y | 1.68 | 1.03-2.75 | |
| Therapy-related APL | |||
| No | .002 | 0.28 | 0.12-0.64 |
| Yes | 3.59 | 1.57-8.20 | |
| CNS involvement at diagnosis | |||
| Absent | .04 | 0.35 | 0.13-0.96 |
| Present | 2.89 | 1.05-7.99 | |
| RFS | |||
| Sex | |||
| Male | .03 | 1.53 | 1.04-2.25 |
| Female | 0.66 | 0.45-0.97 | |
| CNS involvement at diagnosis | |||
| Absent | <.001 | 0.20 | 0.10-0.42 |
| Present | 4.94 | 2.63-11.1 | |
| Treatment groups | |||
| ATRA/chemotherapy | <.001 | 13.59 | 3.33-55.45 |
| IV-ATO/ATRA | 0.25 | 0.08-0.79 | |
| Oral-AAA | 0.07 | 0.02-0.30 | |
| Year of diagnosis | |||
| 2001-2011 | <.001 | 3.48 | 1.97-6.12 |
| 2012-2022 | 0.29 | 0.16-0.51 | |
| OS | |||
| Age | |||
| ≤50 y | .002 | 0.52 | 0.35-0.78 |
| >50 y | 1.92 | 1.28-2.89 | |
| CNS involvement at diagnosis | |||
| Absent | <.001 | 0.15 | 0.09-0.26 |
| Present | 6.55 | 3.80-11.30 | |
| APL-DS | |||
| Absent | <.001 | 0.31 | 0.20-0.50 |
| Present | 3.14 | 2.02-4.90 | |
| Induction regimen | |||
| ATRA/chemotherapy | .03 | 2.33 | 1.23-4.42 |
| IV-ATO/ATRA | 0.72 | 0.33-1.60 | |
| Oral-AAA | 0.43 | 0.22-0.80 |
| Prognostic indicators . | P value . | HR for inferior survival . | 95% CI . |
|---|---|---|---|
| 60-d survival | |||
| CNS involvement at diagnosis | |||
| Absent | <.001 | 0.06 | 0.03-0.13 |
| Present | 15.95 | 7.56-33.63 | |
| Induction regimens | |||
| Non-ATO containing | <.001 | 5.33 | 2.30-12.35 |
| ATO containing | 0.19 | 0.08-0.44 | |
| Treatment groups | |||
| ATRA/chemotherapy | <.001 | 5.53 | 2.24-13.68 |
| IV-ATO/ATRA | 0.22 | 0.03-1.68 | |
| Oral-AAA | 0.18 | 0.07-0.45 | |
| Post–60-d OS | |||
| Sex | |||
| Male | .02 | 1.87 | 1.12-3.11 |
| Female | 0.54 | 0.32-0.90 | |
| Age | |||
| ≤50 y | .04 | 0.60 | 0.36-0.97 |
| >50 y | 1.68 | 1.03-2.75 | |
| Therapy-related APL | |||
| No | .002 | 0.28 | 0.12-0.64 |
| Yes | 3.59 | 1.57-8.20 | |
| CNS involvement at diagnosis | |||
| Absent | .04 | 0.35 | 0.13-0.96 |
| Present | 2.89 | 1.05-7.99 | |
| RFS | |||
| Sex | |||
| Male | .03 | 1.53 | 1.04-2.25 |
| Female | 0.66 | 0.45-0.97 | |
| CNS involvement at diagnosis | |||
| Absent | <.001 | 0.20 | 0.10-0.42 |
| Present | 4.94 | 2.63-11.1 | |
| Treatment groups | |||
| ATRA/chemotherapy | <.001 | 13.59 | 3.33-55.45 |
| IV-ATO/ATRA | 0.25 | 0.08-0.79 | |
| Oral-AAA | 0.07 | 0.02-0.30 | |
| Year of diagnosis | |||
| 2001-2011 | <.001 | 3.48 | 1.97-6.12 |
| 2012-2022 | 0.29 | 0.16-0.51 | |
| OS | |||
| Age | |||
| ≤50 y | .002 | 0.52 | 0.35-0.78 |
| >50 y | 1.92 | 1.28-2.89 | |
| CNS involvement at diagnosis | |||
| Absent | <.001 | 0.15 | 0.09-0.26 |
| Present | 6.55 | 3.80-11.30 | |
| APL-DS | |||
| Absent | <.001 | 0.31 | 0.20-0.50 |
| Present | 3.14 | 2.02-4.90 | |
| Induction regimen | |||
| ATRA/chemotherapy | .03 | 2.33 | 1.23-4.42 |
| IV-ATO/ATRA | 0.72 | 0.33-1.60 | |
| Oral-AAA | 0.43 | 0.22-0.80 |
CI, confidence interval; HR, hazard ratio.